News
Article
ePT--the Electronic Newsletter of Pharmaceutical Technology
Author(s):
Microbix Biosystems has established a team of experts to help manufacturers boost their production of influenza vaccine.
Toronto, ON, Canada (Aug. 13)-Microbix Biosystems has established a team of experts to help manufacturers boost their production of influenza vaccine. The “Special Workgroup for Applied Technology Transfer” or “SWATT” group, working with the company’s “VirusMax” technology, spends several weeks at each facility to help implement the technology and train personnel.
The VirusMax technology is designed to increase the virus yield from eggs by effectively recovering the virus. “Our technology can be installed very quickly, and with limited capital costs into existing manufacturing processes,” said William J. Gastle, CEO of Microbix, in a prepared statement. According to the company, the technology has been shown to double vaccine production.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.